Enabling t-cell therapy with oncolytic viruses

TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy.

About

TILT Biotherapeutics Ltd is the leading company globally working in the area of enabling tumor T-cell therapy with oncolytic viruses.

TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of  solid tumors as currently achieved for CD19+ hematological tumors.

Team

Board of Directors

hemminki

Akseli Hemminki

MD, PhD, Founder & CEO and Chairman of the Board

hemminki

Akseli Hemminki

MD, PhD, Founder & CEO and Chairman of the Board

Following an award-winning PhD in cancer genetics, Dr Hemminki completed his MD and then moved to the US to learn about gene therapy in 2000. He fell in love with oncolytic viruses and helped set up three clinical trials at the University of Alabama at Birmingham. Subsequent to returning to Finland he specialized in oncology and radiotherapy and set up his research group, the Cancer Gene Therapy Group, at the University of Helsinki. He has won numerous awards, including the Best PhD thesis in the Faculty, the Sigrid Juselius Award, the Duodecim Young Researcher award and the EACR Young European Cancer Researcher Award.

He has been named the Outstanding Young Person of the World in 2006 by Junior Chamber International and is one of the few non-Americans to receive awards from the National Cancer Institute and ASCO. He received the European Research Council Starting Grant in the first round of funding in 2006, when the funding rate was only 3%. He has been involved in a dozen clinical trials, of which most difficult to set up was the first oncolytic virus trial performed in Northern Europe.

He has also pioneered patient-by-patient use of oncolytic virus therapies under the EU Advanced Therapy Directive. In 2008 Hemminki co-founded Oncos Therapeutics Ltd, a company currently involved in clinical translation of several families of oncolytic viruses, whose patent applications were written by Hemminki. Hemminki served as the Chairman of the Board, Chief Scientific Officer, Head of Research and Development and Board member of Oncos”. In 2015 Oncos merged successfully with Targovax AS, of Norway. Hemminki has published more than 240 peer-reviewed manuscripts on cancer research and oncolytic viruses, many of them in the best journals of the field.

Ahopelto-Timo

Timo Ahopelto

M.Sc. (Tech), Strategy Adviser, Member of the Board of Directors

Ahopelto-Timo

Timo Ahopelto

M.Sc. (Tech), Strategy Adviser, Member of the Board of Directors

Timo Ahopelto is an experienced serial entrepreneur with a strong track record in the health care and biotechnology area. He was the founding CEO for CRF Health, the global leader in electronic Patient Reported Outcomes technology and services for clinical R&D, today serving most top-tier  pharmaceutical companies globally. At CRF Health, in addition to being a vital part of over 150 clinical trials, Ahopelto started two spin-outs in interactive drug marketing and corporate wellness technology. After CRF Health, Ahopelto founded Lifeline Ventures, which was a first investor and adviser in SuperCell, Valkee, ZenRobotics and Oncos Therapeutics among others. Ahopelto has extensive experience in all aspects of company building and organizing funding.

Arto

Arto Linnervuo

Legal Advisor, Member of the Board of Directors

Arto

Arto Linnervuo

Legal Advisor, Member of the Board of Directors

Arto Linnervuo is a Partner and Head of IP, TMT and Life Sciences practice areas at Castrén & Snellman Attorneys Ltd, the largest law firm in Finland. He has 15 years of experience in advising companies on technology-based industries. In addition to multinational corporations, he continuously advises tech start-up and growth companies on a broad range of legal matters. Well-recognized international legal directories such as The Legal 500, Chambers Europe, Best Lawyers and PLC Which Lawyer rank Arto Linnervuo among Finland’s leading lawyers in the field.

Veli-Matti-Riihimäki2

Veli-Matti Riihimäki

MD, Financial Adviser, Member of the Board of Directors

Veli-Matti-Riihimäki2

Veli-Matti Riihimäki

MD, Financial Adviser, Member of the Board of Directors

Dr Riihimäki is an experienced medical entrepreneur and investor. He was co-founder, human resources manager and a key executive of MedOne Oy, a pioneering private health-care provider in Finland. Following sale of MedOne to Attendo Inc., Dr Riihimäki has been active in both investing and playing a hands-on role in the health care industry. For example, he was CEO of Silmäasema Fennica, a chain of opticians and ophthalmologists. He had a major role in making the company the nationally leading brand, and then took a step back to act as the Chairman of Board. He has been Chief Physician of several local municipalities in Finland and recently started as CEO of MenuMat Oy, a company involved in improving geriatric nutritional services.

Scientific Advisory Board

drenonew

Brigitte Dreno

MD, PhD. Member of the Scientific Advisory Board

drenonew

Brigitte Dreno

MD, PhD. Member of the Scientific Advisory Board

Brigitte Dreno is Head of the Cutaneous Oncology Department and head of the GMP Unit of Cell and Gene Therapy at Nantes University Hospital in France. She is a global leader in the clinical implementation of innovative approaches for the treat of melanoma and other skin cancers. She has performed more than 100 clinical trials in this area, including 20 trials using adoptive cell therapy. In one of those trials she used a virus vector with the goal of enhancing the effect of the treatment.  Of note, she published in 2003 and 2007 the first randomized trial in adjuvant TIL therapy of Stage 3 melanoma, showing after a follow up of more than 12 years a significant increase of overall survival in the subgroup of patients with one melanoma invaded lymph node.  A phase III trial in the adjuvant situation including only stage III with one invaded lymph nodes is ongoing and results will be available in 2016. She has published more than 400 peer reviewed papers in international journals, most of them in the best journals in the field of cancer research, immune-oncology and including the New England Journal of Medicine.

umansky2

Viktor Umansky

PhD, Member of the Scientific Advisory Board

umansky2

Viktor Umansky

PhD, Member of the Scientific Advisory Board

Professor Viktor Umansky has studied tumor related immunosuppression for several decades. His work led him to use adoptive cell therapy and to study the immunosuppressive mechanisms, which limit its activity. He is a global leader in understanding tumor mediated immunosuppression and the models that are used for studying it. He works at the leading European Cancer Center DKFZ in Mannheim and Heidelberg.  Dr Umansky has published 103 peer reviewed papers, and many of these were on various aspects of interactions between tumor and immune cells.

bonouusi

Petri Bono

MD, PhD. Member of the Scientific Advisory Board

bonouusi

Petri Bono

MD, PhD. Member of the Scientific Advisory Board

Petri Bono is Director of the Cancer Center at Helsinki University Central Hospital, the only OECI approved Comprehensive Cancer Center in Northern Europe. There are over 100 MDs and more than 16.000 patient visits to the Center every year making it one of the largest cancer centers in Europe. Dr Bono’s own research has involved many areas of molecular and immunological oncology. As he did his PhD in basic and applied immunology, he is uniquely suited to drive immune-oncology forward clinically.  Dr Bono has participated in numerous clinical trials including early phase immuno-oncological trials and published 60 peer reviewed papers in international journals.

TdG nov 2014a (1)

Tanja de Gruijl

PhD, Member of the Scientific Advisory Board

TdG nov 2014a (1)

Tanja de Gruijl

PhD, Member of the Scientific Advisory Board

Tanja de Gruijl heads the Immunotherapy and Immune-monitoring Lab at the VU University medical center-Cancer Center in Amsterdam, where she has been appointed Professor of Translational Tumor Immunology and holds a Fenna Diemer Lindeboom Chair. She has over 20 years of experience in the field of tumor immunology with over 150 peer-reviewed publications to her name. Her research ranges from preclinical topics to immune-monitoring of Phase I-III clinical trials. Her main line of research is the in vivo targeting and modulation of dendritic cells (DC). Further topics of research include tumor-mediated immune suppression, control of DC differentiation, the effects of cytostatic drugs on DC development and functionality, and the immune potentiation of tumor-draining lymph nodes and the tumor microenvironment. Her research has been supported by fellowships and grants from the Netherlands Organization for Scientific Research (NWO) and the Royal Dutch Cancer Society (KWF) and she is a recipient of a competitive research award of the Prostate Cancer Foundation. She is a member of the Grant Review committee of the Melanoma Research Alliance, a member of the scientific council of the Dutch Cancer Society (KWF), Associate Editor of Cancer Immunology Research, and currently chairs the Dutch Tumor Immunology Working Party.

Inge Marie Svane

Inge Marie Svane

MD, PhD, Member of the Scientific Advisory Board

Inge Marie Svane

Inge Marie Svane

MD, PhD, Member of the Scientific Advisory Board

Inge Marie Svane obtained her MD from the Faculty of Health Science, University of Copenhagen, Denmark (1992) and subsequently her PhD (1997). Professor Svane has held several clinical positions during her professional career, and is currently a Consultant and Head of Immunotherapy at the Department of Oncology, Herlev University Hospital (since 2008). She is Head of disseminated melanoma treatment in Eastern Denmark, In addition, Professor Svane is Director of the Center for Cancer Immune Therapy, Herlev University Hospital (since 2006), Professor of Clinical Cancer Immunotherapy, Faculty of Health Sciences (since 2009), and Chairman of PhD Education in Clinical Cancer Research (since 2010). For the last ten years, Professor Svane has been committed to teaching and supervising undergraduates, postgraduates and postdoctoral scientists at The Faculty of Health, University of Copenhagen. Her scientific research interests are in the treatment of melanoma and immunotherapy. Professor Svane has an extensive publication record, authoring more than 100 scientific publications.

Management

hemminki

Akseli Hemminki

MD, PhD, Founder & CEO and Chairman of the Board

hemminki

Akseli Hemminki

MD, PhD, Founder & CEO and Chairman of the Board

Following an award-winning PhD in cancer genetics, Dr Hemminki completed his MD and then moved to the US to learn about gene therapy in 2000. He fell in love with oncolytic viruses and helped set up three clinical trials at the University of Alabama at Birmingham. Subsequent to returning to Finland he specialized in oncology and radiotherapy and set up his research group, the Cancer Gene Therapy Group, at the University of Helsinki. He has won numerous awards, including the Best PhD thesis in the Faculty, the Sigrid Juselius Award, the Duodecim Young Researcher award and the EACR Young European Cancer Researcher Award.

He has been named the Outstanding Young Person of the World in 2006 by Junior Chamber International and is one of the few non-Americans to receive awards from the National Cancer Institute and ASCO. He received the European Research Council Starting Grant in the first round of funding in 2006, when the funding rate was only 3%. He has been involved in a dozen clinical trials, of which most difficult to set up was the first oncolytic virus trial performed in Northern Europe.

He has also pioneered patient-by-patient use of oncolytic virus therapies under the EU Advanced Therapy Directive. In 2008 Hemminki co-founded Oncos Therapeutics Ltd, a company currently involved in clinical translation of several families of oncolytic viruses, whose patent applications were written by Hemminki. Hemminki served as the Chairman of the Board, Chief Scientific Officer, Head of Research and Development and Board member of Oncos”. In 2015 Oncos merged successfully with Targovax AS, of Norway. Hemminki has published more than 240 peer-reviewed manuscripts on cancer research and oncolytic viruses, many of them in the best journals of the field.

MikkoKuva

Mikko Siurala

MSc, Senior R&D Scientist

MikkoKuva

Mikko Siurala

MSc, Senior R&D Scientist

Trained in genetics and molecular biology, Mr Siurala worked for 5 years at the EMBL affiliated Institute for Molecular Medicine Finland (FIMM). He then became interested in oncolytic viruses and joined the Cancer Gene Therapy Group at the University of Helsinki. Believing in the utility of oncolytic viruses for enhancing T-cell therapies, he joined TILT in November 2013, while continuing to work towards his PhD at the University.

Suvi Parviainen TILT Biotherapeutics

Suvi Parviainen

PhD, Head of Research and Development

Suvi Parviainen TILT Biotherapeutics

Suvi Parviainen

PhD, Head of Research and Development

Suvi Parviainen has extensive experience in cancer biology and gene therapy, especially with oncolytic viruses. She has published 12 scientific papers with an emphasis on tumor immunotherapy. She completed her PhD thesis studies at the Cancer Gene Therapy Group, University of Helsinki and has previous biotechnology experience from Ark Therapeutics Ltd, Kuopio, Finland. In January 2015, Suvi joined TILT Biotherapeutics Ltd as Head of Research and Development. She will be responsible for preclinical research and translation into clinical development.

Elinapicture040416

Elina Koli

MSc, Head of Quality

Elinapicture040416

Elina Koli

MSc, Head of Quality

In addition to love for quality and compliance, Elina Koli has solid bioprocess and manufacturing experience. Before joining TILT as Head of Quality in January 2016, she worked in CAR T cell therapy manufacturing at Clinical Cell and Vaccine Production Facility in the University of Pennsylvania. Her earlier positions include also Production Chemist and Bioproduction Foreman at Reagena Oy, where she was dealing with manufacturing of immunodiagnostic tests with special emphasis on antigen production in cell cultures. She holds a MSc in Biotechnology from the University of Eastern Finland. Currently Elina is responsible for managing the outsourced clinical oncolytic virus production project.

Osterlund_Mona Pic

Mona Österlund

MSc, Head of Clinical Operations

Osterlund_Mona Pic

Mona Österlund

MSc, Head of Clinical Operations

Mona Österlund holds a MSc in Chemistry from the Freie Universität Berlin and has been working with clinical trials since 2001. Starting as a CRA in Germany and during the career having positions as a lead CRA and local project manager in Denmark and Finland she has gained a broad experience in clinical operations working with more than ten different sponsors and with a large amount of different indications. The last three years before joining TILT Biotherapeutics she has focused on oncology studies.

photo ak jan 2016

Aino Kalervo

M.Sci, MS. Head of Business Management

photo ak jan 2016

Aino Kalervo

M.Sci, MS. Head of Business Management

With initial education in molecular biology and business, Aino Kalervo has years of international experience in pharmaceutical industry. She worked for 5 years at Sanofi in Paris, where among other biological products she got interested in viral vectors while prospecting for biotechs within Sanofi’s contract manufacturing organization. She then joined a French biotech company developing therapeutic vaccines as a Competitive Intelligence / Business Development Manager to structure and initiate partnering activities. She served as a key person to initiate collaborations within several biotech and pharma companies. Aino has acquired an extensive technical and business understanding of the biopharmaceutical market through her past research and work. After almost 20 years abroad, she joined TILT Biotherapeutics as the Head of Business Management. Her responsibilities will include fund raising and business development activities.

Pipeline

The company is currently in the preclinical stage. The first clinical trials are expected to start in 2017. The first trial will likely be a Phase 1 trial in metastatic melanoma, with all patients receiving T-cell therapy with tumor infiltrating lymphocytes, while oncolytic virus injections will be given in a dose escalation manner. Second and third trials will utilize a combination of TILT virus with 2) CAR T-cells or 3) a checkpoint antibody for solid tumor indications. More information will be available on this page when opening of the trial is nearer.

Scientific Background

While T-cell therapies have experienced some recent clinical breakthroughs in the treatment of melanoma, leukemia and other tumors, in most trials there is still room for improvement in efficacy. In fact, in most trials most patients have not benefited from treatment.

The best results in T-cell therapy trials, especially with tumor infiltrating lymphocytes (TIL), have been obtained when high dose chemotherapy, with or without whole body irradiation were used as pre-conditioning regimens to enhance the effect of the T-cell graft. In fact, many experts in the field feel that with conventional TIL technology, these highly toxic conditioning regimens are required for efficacy. Moreover, most TIL trials utilize high dose IL-2 (previously known as T-cell growth factor) as a post-conditioning regimen to prolong the activity and viability of the graft. However, both pre- and post-conditioning are toxic regimens causing adverse events including deaths. The patented TILT technology is based on novel oncolytic viruses coding for cytokines. The constructs are unique in structure, sequence and function. Formal patentability and freedom to operate searches have underlined the uniqueness of the TILT approach. While laboratory work has already indicated that TILT technology results in dramatic increases in efficacy in murine models of T-cell therapy, mechanism of action studies are still under way. However, emerging data suggests enhancement of both the recruitment and the anti-tumor activity of the T-cell graft. Importantly, ongoing studies will determine if TILT technology will allow retained or increased efficacy in the absence of pre- and post-conditioning chemotherapy and IL-2, respectively (Figure 1 below). While chimeric antigen receptor (CAR) modified T-cell have already worked well in trials with hematological cancer patients with CD19+ tumors, in solid tumors the results have been disappointing. Our technology has the potential to overcome the identified obstacles for realizing the potential of CAR technology in solid tumors. Thus, with the TILT approach, it may be possible to obtain similar results in solid tumors as currently seen in CD19+ leukemias.

Publications

  • Tähtinen S, Grönberg-Vähä-Koskela S, Lumen D, Merisalo-Soikkeli M, Siurala M, Airaksinen AJ, Vähä-Koskela M, Hemminki A. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol Res. 2015.
http://www.ncbi.nlm.nih.gov/pubmed/25977260
  • Tähtinen S, Kaikkonen S, Merisalo-Soikkeli M, Grönberg-Vähä-Koskela S, Kanerva A, Parviainen S, Vähä-Koskela M, Hemminki A. Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors. PLoS One. 2015;10(6):e0131242.
http://www.ncbi.nlm.nih.gov/pubmed/26107883

Conventional T-CELL therapy

Tilt Technology

Our Technology

1

illu-1

T-cells are collected from tumors (1a) or blood (1b). In the case of 1b, cells are transduced with lentivirus coding for a selected T-cell receptor or chimeric antigen receptor.

Close X

2

illu-2

T-cells are grown in the laboratory in the presence of IL2, also known as T-cell growth factor. Afterwards the process of returning the T-cells into the patient (intravenously) begins.

Close X

3

illu-3

Many T-cells stay in the circulation or go to non-target organs insted of tumor. The few cells that make it to the tumor may rapidly become inactivated because of the immune suppressive tumor microenvironment.

Close X

4

illu-4

TILT virus is injected intratumorally (a) or intravenously (b) and finds its way to the tumor. TILT has patented technology for both intratumoral and intravenous delivery of its oncolytic viruses to tumors.

Close X

5

illu-5

TILT virus replicates and produces cytokines, resulting in recruitment of T-cells from the circulation. Also, as shown in the blow-up the T-cells at the tumor are activated by the cytokine coding oncolytic virus.

tilt-layout-tumor-big

Close X

6

illu-6-2

Tumor responds.

Close X

P1

Enhancement of melanoma adoptive T-cell therapy by adenoviral gene transfer

Four posters featuring TILT technology were presented at the 13th Cancer Immunotherapy Annual Meeting in Mainz, Germany in May 2015. With most browsers, you can zoom in on the poster and the resolution will improve. Links to posters can also be found on the News page.

Close X

P2

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T-cell therapy by breaking tumor tolerance

Close X

P3

Enhancing adoptive T-cell therapy with oncolytic adenovirus encoding CD40-ligand

Close X

P4

Abscopal effect seen with T-cell therapy enhancing oncolyticadenoviruses armed with TNFα and IL-2

Close X

P5

Mikko_ASGCT2016

Posters featuring TILT technology were presented at the American Society of Gene & Cell Therapy 19th Annual Meeting in Washington DC, USA in May 2016. Posters can also be found on the News page.

Close X

P6

ASGCT poster Riikka 2016

Close X

History of T-CELL therapy

2013

Leukemia patients cured with CAR technology

2013

TILT Biotherapeutics is founded

2012

First randomized phase 3 trial with TIL + low dose IL2 completed

2010s

Low-dose IL2 proposed as better tolerated alternative for TIL post-conditioning

2010s

“Young TILs” simplify TIL procedure

2010s

Response rates near 50% and many melanoma patients seem cured with TIL but with significant toxicity

2000s

Engineering of peripheral blood lymphocytes with tumor specific T-cell receptors

2000s

High dose chemotherapy proposed as lymphodepleting preconditioning

2000s

Preconditioning regimens are compared: high dose chemo +/- full body radiation.

1990s

Interleukin 2 is added to the treatment protocol

1990s

Chimeric antigen receptor (CAR) technology for targeting peripheral blood lymphocytes

1983

Discovery of the T cell antigen receptor

1980s

Adoptive T-cell therapies first tested using tumor infiltrating lymphocytes (TIL)

1979

Generation of the first monoclonal T cells (Kendall A. Smith)

1974

T-cell restriction to MHC (Rolf Zinkernagel and (Peter C. Doherty)

1968

Passenger leukocytes identified as significant immunogens in allograft rejection (William L. Elkins and Ronald D. Guttmann)

1961

Discovery of involvement of the thymus in cellular immunity (Jacques Miller)

1960

Discovery of human leukocyte antigens (Jean Dausset and others)

1959

Discovery of lymphocyte circulation (James Gowans)

1953

Graft-versus-host disease (mediated by T-cells)

1944

Demonstration of organ rejection (mediated by T-cells)

1921

Cutaneous allergic reactions (Otto Prausnitz and Heinz Küstner)

1909

Paul Ehrlich proposes the immune surveillance hypothesis of tumor recognition and eradication

1893

Use of live bacteria and lysates to treat tumors (William B. Coley)

1891

Demonstration of cutaneous delayed type hypersensitivity (Robert Koch)

1796

Edward Jenner discovers the benefits of vaccination

Contact

hemminki

Akseli Hemminki

Founder & CEO

akseli@tiltbio.com

TILT Biotherapeutics Ltd

Haartmaninkatu 3, 4th floor, C-wing
00290 Helsinki, Finland

Further Information

The technology of TILT Biotherapeutics is based on work done at the Cancer Gene Therapy Group at the University of Helsinki. For more information about CGTG, please see http://www.hi.helsinki.fi/cgtg/index.htm

For more information about clinical trials, please see http://en.wikipedia.org/wiki/Clinical_trials For more information about phase 1 trials, please see http://www.cancer.net/all-about-cancer/clinical-trials/phases-clinical-trials To search for clinical trials, please see eg. http://clinicaltrials.gov/ For more information about melanoma, please see http://en.wikipedia.org/wiki/Melanoma For information on T-cell therapy, please see http://en.wikipedia.org/wiki/Immunotherapy#T-cell_adoptive_transfer

News & events

June 2016

TILT Biotherapeutics featured in European Biotechnology Vol.15 2016.

European Biotechnology Summer Edition Vol. 15 2016

 

June 2016

16.6.2016 Víctor Cervera-Carrascón, an EU funded student working at TILT wins poster award for his work with anti-PD1 checkpoint inhibition enhanced by TILT technology at Finnish Cancer Institute Symposium.

Victor poster Victor poster 2

May 2016

Posters featuring TILT technology were presented at the American Society of Gene & Cell Therapy 19th Annual Meeting in Washington DC, USA in May 2016

Culture and Characterization of Tumor-Infiltrating Lymphocytes of the Syrian Hamster

Mikko_ASGCT2016

Oncolytic Adenoviruses Armed with TNFa and IL-2 Induce Antitumor Immune Responses and Protection from Tumor Rechallenge

ASGCT poster Riikka 2016

May 2016

6.5.2016 TILT / University of Pennsylvania (Carl June group) collaboration featured in an oral presentation at the American Society of Cell and Gene Therapy meeting in Washington, DC

March 2016

March 2016. Aino Kalervo starts as Head of Business Management at TILT

March 2016

Feb 2016. Víctor Cervera Carrascón starts as a Marie Skłodowska-Curie PhD Student at TILT Biotherapeutics Ltd

February 2016

Feb 2016. Mona Österlund starts as Head of Clinical Operations at TILT

March 2016

Jan 2016. João Manuel Santos started as a Marie Skłodowska-Curie PhD Student at TILT Biotherapeutics Ltd

February 2016

Jan 2016. Elina Koli starts as Head of Quality at TILT

November 2015

Slush.php

12 Nov 2015 Timo Ahopelto interviews Akseli Hemminki on the Green Stage at
SLUSH 2015 (attendance 15 000) http://www.slush.org/

https://www.youtube.com/watch?v=5bQKUwioaz4

September 2015

19.9.2015 TILT technology presented in an invited talk at the European
Society of Gene and Cell Therapy meeting http://www.esgct.eu/congress.aspx

September 2015

TILT Biotherapeutics Ltd, VU University medical center (VUmc) and ORCA Therapeutics announce EU funded Marie Curie Early Stage Researcher positions starting in early 2016.
Application deadline 20.09.2015.

www.academictransfer.com/employer/VUMC/vacancy/29801/lang/en/

June 2015

TILT Biotherapeutics featured in Nature Reviews Drug Discovery

http://www.nature.com/nrd/journal/v14/n6/full/nrd4643.html

January 2015

Suvi Parviainen joins TILT as Head of R&D

December 2014

First Scientific Advisory Board meeting held

December 2014

TILT receives 2 year government loan from TEKES

October 2014

TILT science presented in an invited talk at the European Society of Cell and Gene Therapy

April 2014

TILT technology featured in an invited presentation at the Oncolytic Viruses Meeting in Oxford, UK

December 2013

TILT featured in Talouselämä
http://www.talouselama.fi/%20/a2221261

October 2013

Akseli Hemminki presents on Oncolytic vaccines for treatment of cancer at the Progress in Vaccination against Cancer meeting in Amsterdam, the Netherlands.

August 2013

Seed funding round closed following investments by angels, Lifeline Ventures Fund, Finnish government (TEKES) and Finnish Invention Fund (Keksintösäätiö).

April 2013

TILT Biotherapeutics Ltd is founded